Editor’s Note: The story has been updated to replace the erroneous content published earlier.
Tuesday, Emergent BioSolutions Inc. (NYSE:EBS) received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to deliver millions of doses of four medical countermeasures.
These contract modifications will help ensure continued supply/stockpiling of critical medical countermeasures to address biological threats and emergencies against anthrax, smallpox, and botulism.
The four awards include:
- A contract modification valued at $30.0 ...